In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT_{1A} Receptor Agonist for the Treatment of Schizophrenia

Guangqing Xiao \textsuperscript{1} · Yu-Luan Chen \textsuperscript{1} · Nina Dedic \textsuperscript{1} · Linghong Xie \textsuperscript{1} · Kenneth S. Koblan \textsuperscript{1} · Gerald R. Galluppi \textsuperscript{1}

Received: 7 January 2022 / Accepted: 20 April 2022 / Published online: 28 April 2022
© The Author(s) 2022

Abstract

Purpose Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT_{1A} agonist activity currently in clinical development for the treatment of schizophrenia. The objectives of the current study were to characterize the in vitro ADME properties, preclinical PK, and to evaluate the DDI potential of ulotaront and its major metabolite SEP-383103.

Methods Solubility, permeability, plasma protein binding, CYP inhibition and induction, transporter inhibition and uptake studies were conducted in vitro. Phenotyping studies were conducted using recombinant human CYPs and FMOs, human liver microsomes and human liver homogenates. Preclinical plasma and brain pharmacokinetics were determined after a single intraperitoneal, intravenous, and oral administration of ulotaront.

Results Ulotaront is a compound of high solubility, high permeability, and low binding to plasma proteins. Ulotaront metabolism is mediated via both NADPH-dependent and NADPH-independent pathways, with CYP2D6 as the major metabolizing enzyme. Ulotaront is an inducer of CYP2B6, and an inhibitor of CYP2D6, OCT1 and OCT2, while SEP-383103 is neither a CYP inducer nor a potent inhibitor of CYPs and human transporters. Ulotaront exhibits rapid absorption, greater than 70% bioavailability, approximately 3.5 L/kg volume of distribution, 1.5-4 h half-life, 12-43 ml/min/kg clearance, and good penetration across the blood–brain barrier in preclinical species.

Conclusions Ulotaront has been designated as a BCS1 compound by US FDA. The ability of ulotaront to penetrate the blood–brain barrier for CNS targeting has been demonstrated in mice and rats. The potential for ulotaront and SEP-383103 to act as perpetrators of CYP and transporter-mediated DDIs is predicted to be remote.

KEY WORDS blood–brain barrier · CYP2D6 · drug–drug interactions · phenotyping · TAAR1 · ulotaront

ABBREVIATIONS

| ADME | Absorption, distribution, metabolism, and excretion |
| AO   | Aldehyde oxidase |
| BBB  | Blood-brain barrier |
| BCRP | Breast cancer resistance protein |
| BCS  | Biopharmaceutics classification system |
| BSEP | Bile salt export pump |
| CYP  | Cytochrome P450 |
| CNS  | Central nerve system |
| DDI  | Drug-drug interactions |
| FMO  | Flavin-containing monoxygenase |
| HEK293 | Human embryonic kidney 293 cells |
| HLM  | Human liver microsomes |
| MATE | Multidrug and toxin extrusion |
| MAO  | Monoamine oxidase |
| NADPH| Nicotinamide adenine dinucleotide phosphate |
| OAT  | Organic anion transporter |
| OA  | Organic anion transporting polypeptide |
| OCT  | Organic cation transporter |
| P-gp | P-glycoprotein |
| PK   | Pharmacokinetics |
| PBPK | Physiologically based pharmacokinetics |
| TAAR1 | Trace amine-associated receptor 1 |

INTRODUCTION

Ulotaront is a novel investigational drug currently in Phase 3 clinical development for the treatment of patient with schizophrenia for which ulotaront has received US FDA Breakthrough Therapy Designation. In preclinical studies,
ulotaront has demonstrated broad efficacy in animal models of schizophrenia (relating to positive and negative symptoms), as well as in rodent assays that are sensitive to antidepressants (1–3). Unlike all marketed antipsychotic drugs, ulotaront does not exert its effects via blockade of dopamine D2 or serotonin 5-HT1A receptors. Although the mechanism of action of ulotaront has not been fully elucidated, preclinical studies suggest that agonism at TAAR1 and 5-HT1A receptors contributes to its efficacy (1). TAAR1 has emerged as a promising therapeutic target for several neuropsychiatric disorders given its ability to modulate monoaminergic and glutamatergic neurotransmission (4, 5). In particular, TAAR1 agonists have generated interest as potential treatments for schizophrenia and other psychoses due to TAAR1-mediated regulation of dopaminergic circuitry (4, 5).

In a 4-week, randomized, double-blind placebo-controlled Phase 2 clinical trial (NCT02969328), ulotaront (50–75 mg/day, po, flexibly dosed) demonstrated efficacy in the treatment of patients with an acute exacerbation of schizophrenia, with continued improvement observed over a 6-month open-label extension study (NCT02970929) (6, 7). In addition, ulotaront was generally safe and well-tolerated over the acute and open-label extension studies, with a safety profile distinct from medications used to treat schizophrenia (8). Notably, treatment with ulotaront was not associated with extra pyramidal side effects or other movement disorders, supporting its lack of D2 receptor blockade (6–8). In addition, ulotaront had no clinically meaningful effects on weight, lipids, glycemic indices, prolactin, or ECG parameters (including no evidence for prolongation of the QTc interval), all hallmark side effects associated with the current class of antipsychotic drugs.

Population pharmacokinetic (PK) analysis showed that ulotaront was rapidly absorbed and quickly cleared from plasma after oral administration to subjects with schizophrenia (9). Ulotaront exposures increased dose-proportionally at therapeutic dose levels ranging from 25 to 100 mg q.d. (9). Multiple metabolites of ulotaront have been identified from preclinical and clinical in vitro and in vivo studies (10). There are no human unique metabolites. Of the metabolites identified, SEP-383103 was the only major metabolite detected in the plasma of both preclinical and clinical species.

The primary objective of the current study was to characterize the in vitro absorption, distribution, metabolism, and excretion (ADME) profile, and preclinical PK of ulotaront and its major metabolite SEP-383103. The contribution of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent and NADPH-independent enzymes to the metabolism of ulotaront, as well as to the biotransformation from ulotaront to SEP-383013, were investigated. In addition, in vitro studies assessed whether ulotaront and SEP-383103 are substrates, inhibitors, or inducers of human cytochrome P450 (CYP) enzymes and transporters. Finally, the penetration of ulotaront and SEP-383103 across the rodent blood–brain barrier (BBB) was investigated. Results from the in vitro ADME and preclinical PK studies, as well as the potential of CYP and transporter-mediated DDIs involving ulotaront and SEP-383103 are discussed in this paper.

**METHODS**

**Solubility**

The study was conducted at Eurofins BioPharma Product Testing (Columbia, MO). Ulotaront solubility was evaluated as the free base concentration in buffers over a pH range from 1.2 to 6.8 at 37 °C. The buffers used were hydrochloric acid buffer for pH 1.2, acetate buffer for pH 4.5, and phosphate buffer for pH 6.8. Saturated solutions of ulotaront in various pH buffers were allowed to equilibrate using the shake-flask method for 24 h. The concentration and solubility profile of the resulting samples were determined using high-performance liquid chromatography (HPLC) assay.

**Plasma Protein Binding, and Red Blood Cell Partitioning**

The studies were conducted at Huntingdon Life Sciences (Huntingdon, UK). Plasma and whole blood from pooled CD-1 mice, Sprague Dawley (SD) rats, Beagle dogs, Marmoset monkeys, and human healthy volunteers were used for the assays. Plasma protein binding was determined using the ultrafiltration method. 14C-uloataront was incubated with plasma at 37 °C for 1 h. After the incubation, aliquots were sampled and centrifuged at 2,000 g for 5 min, and the concentrations were determined by radioactivity. For red blood cell partitioning, 14C-uloataront was incubated with fresh whole blood at 37 °C for 1 h. Following the incubation, a portion of the whole blood was sampled for radioactivity measurement, a separate portion was taken for measurement of the packed cell volume, and the remainder was centrifuged to obtain plasma for radioactivity measurement. 14C-uloataront was used for all protein binding assays and red blood cell partitioning assays. 14C-uloataront concentrations for protein binding assays were 0.01 to 100 µg/mL, and 14C-uloataront concentrations for red blood cell partitioning assays were 1 to 100 µg/mL.

**Permeability**

Ulotaront permeability study was conducted at Corning (Woburn, MA) using the Caco-2 monolayer system. Ulotaront (1 to 100 µM) was added to the apical and basolateral chambers to determine the permeability in the apical to
basolateral (A to B), and basolateral to apical (B to A) directional, respectively. Transport buffer was Hanks Balanced Salt Solution (HBSS) buffered with 10 mM HEPES (N-[2-Hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid]), pH adjusted to 7.4 with NaOH. Receiver solution was prepared by adding 1% organic solvent to transport buffer. The monolayers were incubated on an orbital shaker at 37 °C, with ambient humidity and CO₂ for the duration of the transport assay. Samples were collected after 45, 90, and 120 min incubations and concentrations were determined by liquid chromatography with tandem mass spectrometry (LC–MS/MS). SEP-383103 permeability study was conducted at Covance (Madison, Wisconsin) using the Caco-2 monolayer system. SEP-383103 (1 and 5 µM) was added to the apical and basolateral chambers to determine the permeability in the apical to basolateral (A to B), and basolateral to apical (B to A) directional, respectively. Samples were collected after a 120-min incubation at 37 °C, and concentrations were determined by LC–MS/MS. For both ulotaront and SEP-383103 studies, digoxin and estrone-3-sulfate were used as the probe substrates of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), respectively.

**Hepatocyte and Liver Microsome Stability**

Hepatocyte stability studies were conducted at Huntingdon Life Sciences (Huntingdon, UK) using cryopreserved hepatocytes from pooled CD-1 mice, SD rats, Beagle dogs, Cynomolgus monkeys, and humans. Ulotaront (1, 10 and 50 µM) was incubated with cryopreserved hepatocytes (1 × 10⁶ cells/mL) in Supplemented Williams’ Medium E containing fetal calf serum for 30 min, 1, 2 and 4 h in an orbital shaking water bath (set at 60 rpm) at 37 °C under an atmosphere of humidified 95% oxygen and 5% CO₂. Samples were then homogenized by ultrasonic disruption. Ulotaront stability in human liver microsome (HLM) stability assays were conducted at Xenotech (Kansas City, Kansas). Ulotaront (1, 10 and 100 µM) was incubated for 240 min with HLM (1 mg protein/mL) in 0.2-mL incubation mixtures containing potassium phosphate buffer (50 mM, pH 7.4), MgCl₂ (3 mM) and EDTA (1 mM, pH 7.4) fortified with an NADPH-generating system and uridine 5’-diphosphoglucuronic acid (UDPGA). The disappearance of ulotaront after incubation with hepatocytes and HLM was analyzed by LC–MS/MS.

**In Vitro Phenotyping**

Ulotaront phenotyping studies were conducted at Xenotech (Kansas City, Kansas) using recombinant human metabolizing enzymes and HLM in 0.2-mL incubation mixtures containing potassium phosphate buffer (50 mM, pH 7.4), MgCl₂ (3 mM) and EDTA (1 mM, pH 7.4) with and without cofactors (mixed solution of an NADPH-generating system and UDPGA). 1⁴C-ulotaront (1, 10 and 100 µM) was incubated with recombinant human CYP enzymes (rCYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4; 25 pmol/mL), and human Flavin-containing Monoxygenase (FMO) enzymes (rFMO1, rFMO3 and rFMO5; 1 mg protein/mL). After 120 min incubation at 37 °C, the disappearance of ulotaront and formation of metabolites was analyzed by LC–MS/MS and radioactivity. Incubations of 1⁴C-ulotaront with control microsomes (from non-transfected insect cells expressed without cytochrome b₅) were included in the experiment as negative controls for the recombinant FMO enzymes. Michaelis–Menten enzyme kinetic constants (Kₘ and Vₘₐₓ) for ulotaront metabolism (as measured by substrate loss) by recombinant CYP2D6 were determined.

The in vitro metabolism of ulotaront was also conducted at Covance (Madison, Wisconsin) using HμRel® System to assess the involvement of CYP2D6 and non-CYP enzymes in ulotaront metabolism. HμRel® human hepatic co-cultures were purchased from HμRel® Corporation (North Brunswick, New Jersey). Ulotaront (2 µM) was incubated with HμRel® hepatocytes at 37 °C in an atmosphere of 5% CO₂, in the absence and presence of 1-aminobenzotriazole (1 mM), or quinidine (1 µM) for 1, 2, 4, 6, 8, 12, 24, and 48 h. Ulotaront disappearance after the incubation was analyzed by LC–MS/MS.

The metabolism of ulotaront and formation of metabolites SEP-363854 and SEP-383103 were further investigated at WuXi AppTec Laboratory Testing Division (Cranbury, New Jersey) using HLM and human liver homogenates. Following ulotaront incubation with HLM (1 mg/mL) or human liver homogenates (0.2 mg/mL) in incubation mixtures containing potassium phosphate buffer (50 mM, pH 7.4), MgCl₂ (3 mM) and EDTA (1 mM, pH 7.4) in the absence and presence of NADPH, the disappearance of ulotaront and the formation of metabolites SEP-383103 and SEP-363854 were monitored using LC–MS/MS. In addition, the formation of metabolite SEP-383103 was monitored using LC–MS/MS following ulotaront incubation with human liver homogenates in the absence and presence of phenelzine (10 µM), a Monoamine Oxidase (MAO) inhibitor (11), or raloxifene (1 µM), an Aldehyde Oxidase (AO) inhibitor (12).

**CYP Inhibition**

In vitro CYP inhibition assessment of ulotaront (0.1 to 100 µM) was conducted at Xenotech (Kansas City, Kansas) using HLM. The inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 (using two different marker substrate reactions; testosterone 6β-hydroxylation and midazolam 1’-hydroxylation) and CYP4A11 was determined. In vitro CYP inhibition assessment of SEP-383103 (0.1 to 100 µM) was...
conducted at Corning (Woburn, Massachusetts) using HLM. The inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 (using two different marker substrate reactions; testosterone 6β-hydroxylation and midazolam 1′-hydroxylation) was determined. Ulotaront or SEP-383103 were incubated with HLM in reaction mixtures containing NADPH-regenerating system and specific probe substrates (at concentrations approximately equal to their apparent $K_m$) of the tested CYPs in 100 mM potassium phosphate buffer (pH 7.4) at 37 °C. LC–MS/MS was used for the quantitation of the metabolites of the probe substrates. Samples were centrifuged to precipitate the proteins, and supernatants were stored at -20 °C for subsequent analyzing metabolites of the probe substrates by LC–MS/MS.

To evaluate time-dependent inhibition of CYP activity, ulotaront or SEP-383103 was preincubated with HLM without and with an NADPH-generating system for 30 min, respectively, prior to the incubation with the probe substrates. Known direct and time-dependent inhibitors of CYP enzymes were used as positive controls in all experiments (Table S1).

**CYP Induction**

In vitro CYP induction assessment of ulotaront (0.3 to 250 μM) was conducted at Xenotech (Kansas City, Kansas), and the in vitro CYP induction assessment of SEP-383103 (0.3 to 100 μM) was conducted at Corning (Woburn, Massachusetts). Both studies used cryopreserved primary human hepatocytes to evaluate the induction of CYP1A2, CYP2B6 and CYP3A4/5. Ulotaront and SEP-383103 were incubated with human hepatocytes from 3 donors for three consecutive days. After the incubation, enzyme induction was determined by measuring changes in mRNA expression using reverse transcription polymerase chain reaction (RT-PCR) and by conducting in situ catalytic enzyme activity assays using specific probe substrates. Phenacetin, buproprion, midazolam and testosterone were used as the probe substrates of CYP1A2, CYP2B6 and CYP3A4/5, respectively. Omeprazole (50 μM), phenobarbital (750 to 1000 μM) and rifampin (10 to 20 μM) were used as positive inducer controls of CYP1A2, CYP2B6 and CYP3A4/5, respectively. Cytotoxicity was evaluated by Lactate Dehydrogenase (LDH) release.

**Transporter Inhibition and Uptake**

In vitro transporter studies of ulotaront were conducted at Solvo (H-6726 Szeged, Közép fasor 52, Hungary). The inhibition and uptake studies with human Multidrug And Toxin Extrusion 1 (MATE1), MATE2-K, Organic Anion Transporter 1 (OAT1), OAT3, Organic Anion Transporting Polypeptide 1B1 (OATP1B1), OATP1B3, Organic Cation Transporter 1 (OCT1), OCT2 were conducted using transfected HEK293 cell lines expressing the transporters; the uptake studies with human P-gp and BCRP were conducted using transfected MDCKII cell lines expressing the transporters, and the inhibition on human P-gp, BCRP and Bile Salt Export Pump (BSEP) were conducted using transfected member vesicles expressing the transporters. Uptake studies were conducted at 4 concentrations of ulotaront: 0.5, 1, 5, and 10 μM for MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2; and 0.25, 0.5, 2.5 and 25 μM for P-gp and BCRP. The inhibition of ulotaront was tested at 2 concentrations: 10 and 100 μM for MATE1, MATE2K, OAT1, OAT3, and OCT2; 75 and 750 μM for OATP1B1, OATP1B3 and OCT1; and 25 and 250 μM for P-gp, BCRP, and BSEP. The IC$_{50}$ on OCT1 and OCT2 was determined at concentrations ranging from 0.3 to 300 μM.

In vitro transporter studies of SEP-383103 were conducted at Covance (Madison, Wisconsin). The inhibition studies with human MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2 were conducted using transfected HEK293 cell lines expressing the transporters; the inhibition and substrate studies with human P-gp and BCRP were conducted using Caco-2 monolayer system. The inhibition was tested at 2 concentrations: 15 and 50 μM for MATE1, MATE2K, OAT1, OAT3, and OCT2; 30 and 100 μM for OATP1B1, OATP1B3 and OCT1; and 25 and 250 μM for P-gp, BCRP, and BSEP. The permeability of SEP-383103 across Caco-2 cell monolayers was determined at 1 and 5 μM.

Transporter prototypical inhibitors and probe substrates were used for both ulotaront and SEP-383103 studies (Table S2).

All in vitro solubility, protein binding, red blood cell partitioning, stability, phenotyping, CYP and transporter studies were conducted in triplicates.

**Preclinical PK**

All animal studies were conducted in accordance with the institutional animal and care with federal regulations and were approved by the respective Institutional Animal Care and Use Committees.

**Penetration across Mouse and Rat BBB**

The distribution of ulotaront and SEP-383103 to mouse brain was conducted at ChemPartner Co., Ltd. (Shanghai, China) after single intraperitoneal (IP) and oral administrations of ulotaront (1, 3, 10 mg/kg) to male C57BL/6 mice. The IP and oral dosing solutions were prepared in 0.9% Saline at a concentration of 0.1, 0.3, 1 mg/mL. The dosing volume was 10 mL/kg for all PK studies. Whole blood samples were
collected by cardiac puncture at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h post IP or oral dosing into test tubes containing K₂EDTA. Blood samples were centrifuged at 4 °C at 2,000 g for 5 min to obtain plasma samples. After blood collection, a mid-line incision was made in the animals’ scalp and skin was retracted. The skull overlaying the brain was removed, and the whole brain was collected, rinsed with cold saline, dried on filter paper, weighed, and snap frozen by placing into dry ice. Brain sample was homogenized with 3 volumes (v/w) of PBS and stored at approximately -70 °C until analysis. Ulotaront and SEP-383103 plasma and brain concentrations were determined using LC–MS/MS.

The distribution of ulotaront to rat brain was conducted at Medicilon/mpi Preclinical Research (Shanghai, China). Ulotaront was formulated in PBS (1.43 g/L Na₂HPO₄, 0.255 g/L KH₂PO₄, 0.21 g/L KCl and 8.04 g/L NaCl, pH 7), and dosed to male SD rats at 10 mg/kg via oral gavage. Blood samples were collected via the cardiac puncture into tubes containing K₂EDTA at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h post dose, and centrifuged to harvest plasma samples for PK analysis. The brain of each animal was collected immediately after the blood collection. The whole brain was harvested, excised, and rinsed by saline, dried by filter paper, and then placed into one tube per animal tissue. Plasma and brain samples were stored at -80 °C until ulotaront concentration determination by LC–MS/MS. Prior to analysis, brain samples were homogenized with buffer at 1:3 ratio right before analysis.

**Preclinical Plasma PK**

Ulotaront rat plasma PK was conducted at Huntingdon Life Sciences (East Millstone, New Jersey). This was a cross-over design with the same male SD rats dosed intravenously then dosed orally after a one week washout period. Ulotaront was formulated in isotonic 100 mM acetate buffer with 70 nM mannitol. A group of three male SD rats received intravenous bolus injection at a dose level of 10 mg/kg, and by oral gavage at a dose level of 50 mg/kg a week later. Blood samples were collected from each animal into tubes containing K₂EDTA at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 18, 24, and 48 h post dose. Plasma samples were obtained by centrifugation of collected blood and stored at -80 °C until ulotaront concentration determination by LC–MS/MS. At the end of the treatment period, all animals were returned to the in-house colony.

Ulotaront monkey plasma PK was conducted at Medicilon/mpi Preclinical Research (Shanghai, China). Ulotaront was formulated in PBS (1.43 g/L Na₂HPO₄, 0.255 g/L KH₂PO₄, 0.21 g/L KCl and 8.04 g/L NaCl, pH 7), and dosed to male Rhesus monkeys via a single intravenous injection or a single oral gavage at 5 mg/kg. Blood samples were collected via the cardiac puncture into tubes containing K₂EDTA at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 h post dose. Plasma samples were obtained by centrifugation of collected blood and stored at -80 °C until ulotaront concentration determination by LC–MS/MS. At the end of the treatment period, all animals were returned to the in-house colony.

All preclinical plasma and brain PK studies on ulotaront and the major metabolite SEP-383103 were conducted with three animals for each dose and route of administration of ulotaront. Ulotaront doses ranging from 1 to 5 mg/kg for dog and monkey PK were selected mainly to evaluate the PK performance. Higher doses for mouse and rat PK were selected to support both PK and pharmacology studies. PK analyses were performed using the non-compartmental model with Phoenix® WinNonlin™ software (version 6.3 to 8.2, Pharsight Corporation).

**Ulotaront and Metabolite Quantification**

For all *in vitro* and *in vivo* studies discussed in this paper, the concentrations of ulotaront and metabolites SEP-383103 and SEP-363854 were determined using either radioactivity, or LC–MS/MS based methods. The LC–MS/MS methods were developed at each research site by using ulotaront, SEP-383103 and SEP-363854 standards. The assay methods are provided in supplemental section. In addition, a sensitive LC–MS/MS method for simultaneous quantification of ulotaront and metabolite SEP-363854 was developed and validated in support of clinical studies (10).

**Data Analysis**

**Hepatic Clearance Calculation**

Hepatic clearance (CL<br> hep) is calculated using the well-stirred model based on intrinsic clearance (CL<int>) determine from *in vitro* hepatocyte stability assays:
Where \( f_u \) is ulotaront unbound fraction in preclinical and clinical plasma determined \textit{in vitro}.

RBC is ulotaront red blood cell partitioning in preclinical and clinical species determined \textit{in vitro}. \( Q_h \) is the hepatic blood flow in preclinical and clinical species (13).

**Red Blood Cell Partitioning**

Ulotaront blood to plasma concentration ratio \( (K_{B/PL}) \) is calculated from the expression:

\[
K_{B/PL} = \frac{C_B}{C_{PL}} = K_{RBC/PL} \times H + (1 - H)
\]

where \( C_B \) and \( C_{PL} \) represent the concentrations in whole blood and plasma, respectively. \( K_{RBC/PL} \) is the red blood cell (RBC) to plasma concentration ratio, and \( H \) is the volume of red blood cells to the total volume of whole blood (hematocrit).

**DDI Assessment**

DDI potential with ulotaront as an inducer of CYP2B6, and a direct inhibitor of CYP2D6 was assessed using the static mechanistic model according to US FDA Guidance (14). Default value 1 was used for ulotaront fraction of absorbed after oral administration \( (F_a) \), and the fraction available after intestinal metabolism \( (F_g) \). The fraction of hepatic clearance mediated by CYP enzymes \( (f_m) \), and the fraction available after intestinal metabolism \( (F_g) \) of CYP2B6 and CYP2D6 probe substrates were based on the simulations using SimCYP (version 20).

**RESULTS**

**Solubility**

The aqueous solubility of ulotaront was determined at three pH values using the shake-flask method. The solubilities at 37 °C determined at pH 1.2, 4.5 and 6.8 were 423.5 ± 1.8, 434.4 ± 0.9 and 437.7 ± 2.7 mg/mL, respectively.

**Plasma Protein Binding, and Red Blood Cell Partitioning**

The binding to plasma proteins and the red blood cell partitioning coefficient of ulotaront were determined at concentrations of 1 to 100 µg/mL for preclinical species, and 0.01 to 100 µg/mL for humans, as described in the methods. The mean values are shown in Table S3. Ulotaront has low binding to animal and human plasma proteins with an unbound fraction greater than 78%. Ulotaront is not preferentially sequestered into animal or human red blood cells. The blood to plasma ratio is close to unity. In addition, neither the protein binding nor the red blood cell partitioning coefficient is concentration dependent.

**Hepatocyte and Liver Microsome Stability**

Ulotaront \textit{in vitro} stability was evaluated in mouse, rat, dog, monkey and human hepatocytes at concentrations of 1, 10 and 50 µM. The intrinsic clearance \( (CL_{int}) \) and hepatic clearance \( (CL_{hep}) \) are summarized in Table S3. Cynomolgus monkey hepatic clearance was calculated based on plasma protein binding and red blood cell partitioning determined for Marmoset monkeys. Ulotaront exhibited low to moderate hepatic clearance in mouse, rat, monkey, and human hepatocytes, but high hepatic clearance in dog hepatocytes. The hepatic clearance determined from mouse, rat, monkey, and human hepatocytes is equivalent to <25% of hepatic blood flow in the corresponding species, however the clearance determined from dog hepatocytes is about 50% of the hepatic blood flow.

The \textit{in vitro} stability of ulotaront was also determined in HLM at 1, 10 and 100 µM. Similar to the observed \textit{in vitro} stability in human hepatocytes, ulotaront showed slow metabolism in HLM. After 240 min incubation with HLM, there was less than 30% disappearance of ulotaront at 1 µM, and essentially no loss at 10 and 100 µM (Figure S1).

**Permeability**

Ulotaront exhibited high permeability and low efflux ratio across Caco-2 monolayers. The permeability was determined at concentrations from 1 to 100 µM for 45 to 120 min. Under the experimental conditions, the permeability in the A-B direction ranged from \( 22 \times 10^{-6} \) to \( 27 \times 10^{-6} \) cm/s, the permeability in the B-A direction ranged from \( 28 \times 10^{-6} \) to \( 30 \times 10^{-6} \) cm/s, and efflux ratio ranged from 1.1 to 1.3 (Table S4). Similar permeability and efflux ratio were observed across the test concentration range and over the incubation period.

In contrast, SEP-383103 (1 and 5 µM) exhibited much lower permeability across Caco-2 monolayers. At 1 µM test concentration, the mean permeability values in the A-B and B-A directions were \( 2.3 \times 10^{-6} \) and \( 2.7 \times 10^{-6} \) cm/sec, respectively, and the efflux ratio was 1.2. At 5 µM test concentration, the mean permeability values in the A-B and B-A directions were \( 1.3 \times 10^{-6} \) and \( 2.4 \times 10^{-6} \) cm/sec, respectively, and the efflux ratio was 1.9.
Phenotyping

In vitro studies were conducted to investigate the major enzymes involved in ulotaront metabolism, as well as in the biotransformation from ulotaront to the metabolites.

Whether ulotaront metabolism was mediated by human CYP and FMO enzymes was investigated by analyzing parent disappearance after incubating $^{14}$C-ulotaront with a panel of recombinant CYP and FMO enzymes. Among the recombinant human CYP enzymes (rCYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) and FMO enzymes (rFMO1, FMO2 and FMO3) tested, significant loss of ulotaront was observed after the incubation with recombinant CYP2D6. Approximately 97% and 42% of ulotaront were metabolized after a 120-min incubation with recombinant CYP2D6 at 10 and 100 µM, respectively (Fig. 1A). More than 80% of ulotaront disappearance was observed over a 40 min incubation with recombinant CYP2D6 at lower concentrations (0.1, 1 and 10 µM) (Fig. 1B). The Michaelis–Menten enzyme kinetic constants ($K_m$ and $V_{max}$) for CYP-2D6-mediated metabolism were then determined as measured by ulotaront disappearance (Fig. 1C). The $K_m$ was 4.84 ± 1.05 µM, and $V_{max}$ was 7.42 ± 0.42 pmol/pmolCYP2D6/min.

In addition to monitoring ulotaront disappearance, the formation of metabolites after incubation with recombinant CYP and FMO enzymes was also analyzed by radioactivity. The relative abundance of metabolite formation is summarized in Table I, which indicates that the formation of the metabolites is mainly determined by CYP2D6.

Because of the low metabolism from in vitro stability studies using HLM or human hepatocytes, ulotaront metabolism was also investigated by incubating ulotaront (2 µM) with HµRel® hepatocytes for longer incubation. The impact of pan CYP inhibitor 1-aminobenzotriazole (1 mM) (15), and strong CYP2D6 inhibitor quinidine (1 µM) (16) on the metabolism was also examined to elucidate the role of non-CYP enzymes in ulotaront metabolism. The study indicated that ulotaront was metabolically stable under the experimental conditions. Further incubation for up to 48 h only led to approximately 10% loss of ulotaront. Pre-treatment with 1-aminobenzotriazole and quinidine slightly reduced metabolism, which is consistent with the involvement of CYP2D6 in ulotaront metabolism as observed from studies using recombinant human CYP enzymes.

Multiple metabolites were identified in preclinical and clinical in vitro and in vivo studies, among them are SEP-383103 and SEP-363854. SEP-383103 is a major metabolite identified in the plasma of mice, rats, rabbits, dogs, monkeys, and humans after a single dose or repeat dose of ulotaront. SEP-363854 is identified as an abundant metabolite from in vitro studies, a major metabolite in the plasma of dogs and rabbits, but as a minor metabolite in the plasma of mice, rats, monkeys and humans. Using human liver homogenates, ulotaront metabolism and the biotransformation from ulotaront to metabolites SEP-383103 and SEP-363854 were investigated. Ulotaront was also metabolically stable in vitro even incubating with human liver homogenates at a low concentration (0.1 µM). There was less than 15% ulotaront disappearance after 240 min incubation, and ulotaront disappearance was similar in the presence of NADPH in comparison to in the absence of NADPH (Fig. 2A), suggesting NADPH-independent pathways are likely involved in ulotaront metabolism. Consistent with
the role of NADPH-independent pathways in ulotaront metabolism, metabolite formation analyses showed while SEP-363854 was predominately formed in the presence of NADPH at 37 °C for 240 min at 0.1 µM, more SEP-383103 was formed in the absence of NADPH (Fig. 2B and 2C). To identify the NADPH-independent enzymes that mediate the biotransformation, the formation of metabolites SEP-363854 and SEP-383103 was determined in the presence of phenelzine (10 µM) and raloxifene (1 µM), or Raloxifene (1 µM) at 37 °C for 240 min. Data are presented as mean±S.D.

**Table 1** Relative Abundance of Metabolite Formed from Recombinant Human CYP and FMO Incubation

| Metabolites | CYP1A2 | CYP2B6 | CYP2C8 | CYP2C9 | CYP2C19 | CYP2D6 | CYP3A4 | FMO1 | FMO2 | FMO3 |
|-------------|--------|--------|--------|--------|---------|--------|--------|------|------|------|
| SEP-363854  | +      | +      |        | +      | +       | +      | +      |      |      |      |
| M1          | +      | +      | +      | +      | +       | +      | +      |      |      |      |
| M2          | +      | +      | +      | +      | +       | +      | +      |      |      |      |
| M4          | +      | +      | +      | +      | +       | +      | +      |      |      |      |
| M6          | +      | +      | +      | +      | +       | +      | +      |      |      |      |
| M7          | +      | +      | +      | +      | +       | +      | +      |      |      |      |
| M10         | +      | +      | +      | +      | +       | +      | +      |      |      |      |
| M11         | +      | +      | +      | +      | +       | +      | +      |      |      |      |
| M12         | +      | +      | +      | +      | +       | +      | +      |      |      |      |

Relative abundance of metabolites is based on radioactivity.

**Fig. 2** Phenotyping studies using human liver homogenates. A: Percentage remaining of ulotaront following incubation in the presence and absence of NADPH at 37 °C for 240 min at 0.1 µM. B: SEP-383103 formation after incubating ulotaront (10 µM) with human liver homogenates in the presence and absence of NADPH at 37 °C for 240 min. C: SEP-363854 formation after incubating ulotaront (10 µM) with human liver homogenates in the presence and absence of NADPH at 37 °C for 240 min. D: Formation of SEP-383103 and SEP-363854 after incubating ulotaront (10 µM) with human liver homogenates in the absence of NADPH, and the presence and absence of MAO inhibitor Phenelzine (10 µM), or Raloxifene (1 µM) at 37 °C for 240 min. Data are presented as mean±S.D.

CYP Inhibition

The direct and time-dependent CYP inhibition by ulotaront and the major metabolite SEP-383103 were evaluated using HLM. Ulotaront and SEP-383103 concentrations were selected so that the highest test concentrations were at least 50-fold greater than the unbound Cmax observed from clinical studies (9). At test concentrations ranging from 0.1 to 100 µM, ulotaront showed direct inhibition only on CYP2D6 respectively. Phenelzine (10 µM) and raloxifene (1 µM) also inhibited SEP-363854 formation by 20% and 24%, respectively (Fig. 2D).
with an IC$_{50}$ value of 68 μM, but did not show direct inhibition on CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5. Ulotaront showed similar inhibition on CYP2D6 after preincubating with HLM for 30 min without and with an NADPH-generating system, therefore ulotaront is not a time-dependent inhibitor of CYP2D6. In addition, there was no evidence of time-dependent inhibition on CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5.

SEP-383103 did not show direct or time dependent inhibition on CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP3A4/5 at test concentrations ranging from 0.1 to 100 μM.

**CYP Induction**

The potential to induce CYP1A2, CYP2B6, and CYP3A4/5 was investigated by incubating ulotaront and the major metabolite SEP-383103 with cryopreserved primary human hepatocytes from 3 donors for three consecutive days. Under the experimental conditions, ulotaront (0.3 to 250 μM) did not induce the mRNA expression or enzymatic activity of CYP1A2 or CYP3A4/5. Ulotaront did not induce CYP2B6 at concentrations less than 30 μM, but induced CYP2B6 mRNA expression and enzymatic activity of hepatocytes from two donors (lot HC10-23 and HC7-25) in a concentration dependent manner at concentrations ranging from 100 μM to 250 μM. Ulotaront induced CYP2B6 mRNA expression up to 6.48-fold and CYP2B6 enzymatic activity up to 7.19-fold, respectively. CYP2B6 induction parameters for mRNA expression and enzymatic activity are summarized in Table II.

Under the experimental conditions, SEP-383103 did not induce the mRNA expression or enzymatic activity of CYP1A2, CYP2B6, and CYP3A4/5 at concentrations ranging from 0.3 to 100 μM.

**Transporter Uptake and Inhibition**

*In vitro* studies using transfected HEK293 cell lines or membrane vesicles were conducted to determine if ulotaront is a substrate or inhibitor of human efflux and uptake transporters. The transporters that were evaluated included efflux transporters P-gp, BCRP, and BSEP; and uptake transporters MATE1, MATE2-K, OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3. The study indicated ulotaront is not a substrate of human P-gp or BCRP since the efflux ratios were less than 2, and the permeability and efflux ratio were not affected in the presence of the PSC833 and Ko143, the inhibitors of P-gp and BCRP (17, 18), respectively. Ulotaront is not a substrate of human MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2 either since there was less than twofold uptake to transfected cells/vesicles in comparison to mock cells/vesicles.

The inhibition potential of ulotaront on efflux and uptake transporters was tested at 2 concentrations as described in the methods. At the test concentrations, ulotaront did not show significant inhibition on P-gp, BCRP, BSEP, MATE1, MATE2-K, OAT1, OAT3, OATP1B1 or OATP1B3, but exhibited inhibition of OCT1- and OCT2-mediated uptake of metformin, a probe substrate of OCT1 and OCT2 (19, 20). The inhibition was therefore further conducted at multiple concentrations to determine the IC$_{50}$. The IC$_{50}$ values for OCT1 and OCT2 are 18.37 μM, and 1.27 μM, respectively (Figure S2).

Whether SEP-383103 is an inhibitor of human P-gp, BCRP, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2 was investigated at 2 concentrations as described in methods. Of the transporters evaluated, SEP-383103 only showed weak inhibition on OAT3 (~35% inhibition at 50 μM) and MATE1 (~20% inhibition at 50 μM).

**CYP-mediated DDI Assessment**

Since ulotaront is an inducer of CYP2B6, and an inhibitor of CYP2D6, CYP-mediated DDI potential with ulotaront as the perpetrator was assessed using the static mechanistic model according to US FDA guidance (14). Bupropion and dextromethorphan were selected as the probe substrates of CYP2B6 and CYP2D6 (21–23), respectively. The fraction of bupropion hepatic clearance by CYP2B6 ($f_{m}$), the fraction of dextromethorphan hepatic clearance by CYP2D6 ($f_{m}$), and the fraction available of bupropion or dextromethorphan after intestinal metabolism ($F_g$) were based on the simulations using SimCYP (version 20). Ulotaront maximum unbound hepatic inlet concentration ([I]$_h$) and enterocyte concentration ([I]$_g$) were based on the absorption rate $k_a$ (0.99 h$^{-1}$) and $C_{max}$ (312 ng/mL at the intended dose of 100 mg) from clinical studies (9). The DDI assessments indicate concomitant ulotaront leads to 17% decrease in bupropion AUC, and 19% increase in dextromethorphan AUC (Table III).
Penetration across Mouse and Rat BBB

To evaluate the penetration across mouse BBB, ulotaront and SEP-383103 plasma and brain PK were determined following a single IP and oral administration of 10 mg/kg ulotaront to male C57BL/6 mice. Ulotaront was rapidly absorbed and distributed to mouse brain after a single IP and oral administration. Ulotaront brain maximum concentrations were reached within 30 min post dose, and brain exposures (C_{max} and AUC_{inf}) were over fourfold greater than the exposures in plasma (Fig. 3, Figure S3, and Table IV). In contrast, SETP-383013 was barely distributed to the brain. SEP-383013 brain exposures (C_{max} and AUC_{inf}) were at least tenfold lower than the plasma exposures (Fig. 3, Figure S3, and Table IV). The penetration of ulotaront and SEP-383103 across mouse BBB was also investigated following a single IP or oral administration of ulotaront at 1 mg/kg and 3 mg/kg, and similar results were observed.

Ulotaront penetration across rat BBB was investigated following a single oral administration of 10 mg/kg ulotaront to male SD rats. Consistent with the observation from mouse brain distribution study, ulotaront was rapidly absorbed and distributed to brain after oral administration. Ulotaront brain maximum concentrations were reached within 30 min post dose. The brain exposures (C_{max} and AUC) were over two-fold greater than the exposures in plasma, and the cerebrospinal fluid (CSF) exposures (C_{max} and AUC) were about 60–85% of the exposures in plasma (Table IV).

Preclinical Plasma PK

Ulotaront plasma pharmacokinetics in preclinical species were determined after a single oral and intravenous administration to male SD rats, male Beagle dogs and male Rhesus monkeys. The mean PK parameters are summarized in Table V, and concentration–time profiles are plotted in Figs. 4A-4C. Parts of the results from the rat and Rhesus monkey PK studies have been included in a previous publication (1). Following a single oral dose, ulotaront was rapidly absorbed with the maximum plasma concentrations

Table III Assessment of CYP-mediated DDI

| Victim | Perpetrator (ulotaront, 100 mg) | DDI |
|--------|---------------------------------|-----|
|        | Probe substrate | f_m | F_g | I_h (µM) | I_g (µM) | EC_{50} (µM) | E_{max} (fold) | K_i (µM) | AUCR |
| CYP2B6 Induction | Bupropion | 0.41 | 0.99 | 5 | 29.3 | 83.3 | 7.34 | NA | 0.83 |
| CYP2D6 Inhibition | Dextromethorphan | 0.95 | 0.91 | 5 | 29.3 | NA | NA | 34 | 1.19 |

Table IV Ulotaront and SEP-383103 Plasma and Brain PK following a Single IP or PO Administration at 10 mg/kg of Ulotaront

| Species | Route | Analyte | T_{1/2} | T_{max} | C_{max} | B/P ratio | AUC_{inf} | B/P ratio |
|---------|-------|---------|---------|---------|---------|-----------|-----------|-----------|
|         |       |         | hr      | hr      | ng/mL, ng/g | ng*hr/mL, ng*hr/g | ng*hr/mL, ng*hr/g |         |
| Mouse   | IP    | Ulotaront | Plasma | 3.46   | 0.08  | 2857 | 4408 |
|         |       |         | Brain  | 3.55   | 0.25  | 12,267 | 22,483 | 5.1 |
| Mouse   | IP    | SEP-383103 | Plasma | 4.21   | 0.08  | 259 | 893 |
|         |       |         | Brain  | 1.21   | 0.50  | 18.5 | 30.7 | 0.03 |
| Mouse   | PO    | Ulotaront | Plasma | 2.35   | 0.25  | 962 | 3668 |
|         |       |         | Brain  | 2.70   | 0.25  | 5187 | 17,839 | 4.9 |
| Mouse   | PO    | SEP-383103 | Plasma | 2.30   | 0.25  | 155 | 1373 |
|         |       |         | Brain  | 11.60  | 0.25  | 11.88 | 60.2 | 0.04 |
| Mouse   | PO    | Ulotaront | CSF    | 2.03   | 0.25  | 1161 | 4544 | 0.85 |
|         |       |         | Brain  | 2.33   | 0.25  | 3762 | 16,854 | 3.1 |
| Rat*    | PO    | Ulotaront | Plasma | 2.10   | 0.25  | 1750 | 5352 |
|         |       |         | CSF    | 2.03   | 0.25  | 1161 | 4544 | 0.85 |
|         |       |         | Brain  | 2.33   | 0.25  | 3762 | 16,854 | 3.1 |

*Partially reported in (1)
reached in less than 2 h post dose (except 6 h in monkeys). Ulotaront showed high bioavailability (~100% in rats, 92% in dogs, and 71% in monkeys), and half-life between 3 to 4.1 h in preclinical species.

Following a single intravenous administration, ulotaront showed a volume of distribution of approximately 3.5 L/kg, and half-life between 1.6 to 3.1 h in rats, dogs and monkeys. Ulotaront exhibited clearance with less than 50% hepatic blood flow in rats and monkeys, but greater than 50% hepatic blood flow in dogs. The hepatic blood clearance determined in rats, dogs and monkeys after a single intravenous dose were 27.4, 26.8 and 10.7 mL/min/kg, equivalent approximately to 50%, 86% and 25% of hepatic blood flow in rats, dogs, and monkeys, respectively. The amount of ulotaront excreted in rat urine is equivalent to 35.8% of the administered dose. The amounts of ulotaront excreted in the urine of dogs and monkeys were significantly lower, representing 4.8% and 10% of the administered dose in dogs and monkeys, respectively.

**DISCUSSION**

The *in vitro* ADME properties and preclinical pharmacokinetics of ulotaront have been characterized. Ulotaront solubility is not pH dependent and is more than 100-fold greater than the intended clinical dose in 250 mL (100 mg/250 mL = 0.4 mg/mL), the threshold for classification as a highly soluble drug within the test pH range from 1.2 to 6.8 (24). These results demonstrate that ulotaront is highly soluble. The high solubility and high permeability (Table S4) are consistent with the high absorption rate observed from mass balance studies in humans using 

\[ ^{14}C \text{-ulotaront} \] (Data on file at Sunovion). Additionally, the low efflux ratio and high permeability are consistent with ulotaront’s ability to penetrate BBB, which has been demonstrated in mice and rats, and makes ulotaront ideal for CNS targeting.

The metabolic stability of ulotaront in preclinical species was determined *in vitro* using hepatocytes, and *in vivo* after a single dose via intravenous administration. Both *in vitro* and *in vivo* studies indicated low to moderate hepatic clearance in rats and monkeys and high hepatic clearance in dogs (Table IV and Table S3). The *in vivo* to *in vitro* ratio of hepatic clearance for rats, dogs and monkeys is 5.5, 1.7, and 1.3 respectively. Ulotaront elimination in humans is mostly via hepatic clearance, with renal clearance contributing approximately 15% of total clearance. Ulotaront human *in vivo* hepatic blood clearance of 4.0 mL/min/kg [calculated as observed apparent total clearance (7.7 mL/min/kg) × estimated bioavailability (0.7) × fraction of total clearance due to metabolism (0.85) × 1/RBC] is likely within twofold of the hepatic clearance determined *in vitro* (3.9 mL/min/kg, Table S3). Therefore, based on the *in vivo* to *in vitro* ratios cited above, there is a good *in vitro* and *in vivo* correlation of hepatic clearance in dogs, monkeys, and humans, but not in rats, where the ratio was 5.5.

Phenotyping studies using recombinant human CYPs and FMOs indicated that the *in vitro* metabolism of ulotaront is mainly determined by CYP2D6, and to a much lesser extent by CYP1A2, CYP2C19 and FMO1 (Table I, Figs. 1A-1C). Studies using human liver homogenates suggest that both NADPH-dependent and NADPH-independent enzymes are involved in ulotaront metabolism (Fig. 2A), while the biotransformation of ulotaront to SEP-383103 is more determined by NADPH-independent enzymes, such as MAO and AO (Figs. 2B and 2D). Due to the low metabolism when studied *in vitro*, the fraction of ulotaront hepatic clearance (\( f_m \)) by CYPs, FMOs, and NADPH-independent enzymes could not be confidently assigned just based on *in vitro* stability studies. By comparing the apparent clearance observed between subjects carrying CYP2D6 poor metabolizer (PM) and extensive metabolizer (EM) phenotypes from clinical studies, CYP2D6 \( f_m \) was estimated to be 0.53 (Data on file at Sunovion).

Ulotaront is a reversible inhibitor of CYP2D6 and an inducer of CYP2B6 (Table II). However, assessments using
either the static mechanistic model (Table III) or PBPK modeling (Data on file at Sunovion) predict that concomitant ulotaront leads to less than 25% change in probe substrate exposures (e.g., $0.8 < \text{AUCR} < 1.25$), suggesting CYP-mediated DDI potential with ulotaront as the perpetrator is remote.

Most of the inhibitors for renal transporters OCT2 and MATE1 or MATE2K are overlapped, although relatively specific inhibitors for MATE1 and MATE2K such as famotidine, nizatidine and pyrimethamine, and relatively specific inhibitors for OCT2 such as disopyramide, have been identified (25–29). In this paper, we report that ulotaront is an inhibitor of OCT2 but not MATE1 or MATE2K (Figure S2). PBPK simulation suggests concomitant ulotaront likely will not affect the PK of OCT2 substrates to a clinically meaningful extent (Data on file at Sunovion), although this remains to be evaluated and confirmed in an ongoing clinical DDI study.

In preclinical species, ulotaront exhibited rapid absorption, moderate volume of distribution, and high bioavailability (Table V). The high bioavailability in monkeys is consistent with the low hepatic clearance. However, the high bioavailability in rats and dogs was not consistent with the moderate to high clearance determined in vitro and in vivo. The reason for the disconnection is not known. After a single IP or oral dose, ulotaront was well distributed to mouse and rat brain, with the total brain exposures being over fourfold and twofold greater than the total plasma exposures in mice and rats, respectively (Table IV). Ulotaront’s ability to penetrate mouse and rat BBB is consistent with the high permeability and not subjected to P-gp or BCRP mediated efflux.

SEP-383103 is not an inhibitor nor is it an inducer of major human CYP enzymes. It is not a potent inhibitor of human transporters either. Although it showed inhibition of OAT3 and MATE1, the $IC_{50}$ is at least 50-fold higher than SEP-383103 unbound $C_{\text{max}}$ at steady state after repeat dose of 100 mg ulotaront. Therefore, the potential for SEP-383103 to be a perpetrator of CYP- and transporter-mediated DDI is remote. In contrast to ulotaront, SEP-383013 was barely distributed to mouse brain. The poor ability to penetrate mouse BBB may be partially explained by the low permeability. SEP-383103 demonstrated no significant activities in an in vitro broad panel receptor screen (internal data). Together with the low BBB penetration in mice, these results suggest that SEP-383103 is not CNS active.

**CONCLUSION**

Ulotaront is a novel, CNS-active compound currently in Phase 3 clinical development for the treatment of schizophrenia. In contrast to all marketed antipsychotic drugs, ulotaront does not exert its efficacy via blockade of dopamine $D_2$ or the serotonin 5-HT$_{2A}$ receptors. Although the mechanism of action of ulotaront has not been fully elucidated, preclinical studies indicate that agonist activity at TAAR1 and 5-HT$_{1A}$ receptors contributes to its efficacy.

Ulotaront has favorable chemical-physical properties, high solubility, high permeability, low binding to plasma proteins, and possesses all attributes of a Biopharmaceutics Classification System (BCS) 1 compound. The ability of ulotaront to penetrate the BBB for CNS targeting has been demonstrated in mice and rats. Ulotaront metabolism
is determined by both NADPH-dependent and NADPH-independent enzymes, with CYP2D6-mediated metabolism as the major pathway though the metabolism mediated by non-CYP enzymes remains to be further investigated. Although ulotaront is an inducer of CYP2B6, and an inhibitor of CYP2D6 and OCTs, the potential for ulotaront to be a perpetrator of CYP or transporter-mediated DDIs is projected to be remote.

The biotransformation of ulotaront to the major metabolite SEP-383013 is largely determined by NADPH-independent enzymes including MAO and AO. SEP-383013 exhibits low permeability and is not well distributed to the brain, suggesting lack of CNS activity. CYP or transporter-mediated DDI potential with SEP-383103 as a perpetrator is remote.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11095-022-03267-1.

Acknowledgements Sunovion discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube® platform and associated artificial intelligence algorithms. Some DMPK studies discussed in this paper were managed by Patrick Koch. The authors would like to thank Colleen Synan for a thoughtful review of the manuscript.

Author contributions Guangqing Xiao, Yu-Luan Chen, Nina Dedic and Linghong Xie designed the experiments, and analyzed the data. Guangqing Xiao, Yu-Luan Chen, Nina Dedic, Linghong Xie, Kenneth S. Koblan and Gerald R. Galluppi wrote the manuscript.

Funding This study was fully funded by Sunovion Pharmaceuticals Inc. and did not receive any special grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declarations Conflict of interest statement The authors declare no conflict of interest. All authors are employees of Sunovion Pharmaceuticals Inc.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther. 2019;371(1):1–14.
2. Begni V, Sanson A, Luoni A, Sensini F, Grayson B, Munni S, et al. Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856. Int J Mol Sci. 2021;22(8):4119. https://doi.org/10.3390/ijms2084119.
3. Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018;23(1):59–69.
4. Berry MD, Gainedinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. Pharmacol Ther. 2017;180:161–80.
5. Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. Int J Mol Sci. 2021;22(24):13185. https://doi.org/10.3390/ijms222413185.
6. Koblan KS, Kent J, Hopkins SC, Krystel JH, Cheng H, Goldman R, et al. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. N Engl J Med. 2020;382(16):1497–506.
7. Correll CU, Koblan KS, Hopkins SC, Li Y, Heather D, Goldman R, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPI Schizophr. 2021;7(1):63.
8. Hopkins SC, Ogirala A, Worden M, Koblan KS. Describing Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021;41(12):1067–73.
9. Galluppi GR, Polhamsus DG, Fisher JM, Hopkins SC, Koblan KS. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia. CPT Pharmacometr Syst Pharm. 2021;10(10):1245–54.
10. Chen YL, Shi Y, Lafayette A, Shi L, Koblan KS, Galluppi GR. A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study. J Pharm Biomed Anal. 2022;207:114404.
11. Matveychuk D, MacKenzie EM, Kumpula D, Song MS, Holt A, Kar S, et al. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2022;42(1):225–42.
12. Barr JT, Jones JP. Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. Drug Metab dispos. 2013;41(1):24–9.
13. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–5.
14. U.S. Food and Drug Administration. In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. Guidance for Industry. 2020.
15. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab. 2010;11(8):678–85.
16. Muralidharan G, Cooper JK, Hawes EM, Korchinski ED, Midha KK. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolizers of debrisoquine. Eur J Clin Pharmacol. 1996;50(1–2):121–8.
17. Bark H, Choi CH, PSC833, cyclosporine analogue, downregulates MDRI expression by activating INK/c-Jun/AP-1 and suppressing NF-kappaB. Cancer Chemother Pharmacol. 2010;65(6):1131–6.
18. Chimezie C, Ewing A, Schexnayder C, Bratton M, Glotser E, Skripnikova E, et al. Glyceollin Effects on MRP2 and BCRP in Caco-2 Cells, and Implications for Metabolic and Transport Interactions. J Pharm Sci. 2016;105(2):972–81.
19. Zamek-Gliszczynski MJ, Chu X, Cook JA, Custodio JM, Galetin A, Giacomini KM, et al. ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision. Clin Pharmacol Ther. 2018;104(5):781–4.

20. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009;19(7):497–504.

21. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics. 2013;23(3):135–41.

22. Storelli F, Matthey A, Lenglet S, Thomas A, Desmeules J, Daali Y. Impact of CYP2D6 Functional Allelic Variations on Phenocrystal and Drug-Drug Interactions. Clin Pharmacol Ther. 2018;104(1):148–57.

23. Wang J, Zhang ZY, Lu S, Powers D, Kansra V, Wang X. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. Support Care Cancer. 2019;27(3):819–27.

24. U.S. Food and Drug Administration. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for Industry. 2017.

25. Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem. 2011;54(13):4548–58.

26. Morrissey KM, Stocker SL, Chen EC, Castro RA, Brett CM, Giacomini KM. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. Clin Pharmacokinet. 2016;55(4):495–506.

27. Shen H, Liu T, Jiang H, Titsch C, Taylor K, Kandoussi H, et al. Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. Drug Metab Dispos. 2016;44(2):238–49.

28. Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, et al. The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet. 2016;55(6):711–21.

29. Xiao G, Rowbottom C, Boiselle C, Gan LS. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K. Pharm Res. 2018;35(8):159.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.